Bioequivalence of dispersed stavudine: Opened versus closed capsule dosing

Antiviral Therapy

Volumn 16, Issue 7, 2011, Pages 1131-1134

  Innes, Steve ^a   Norman, Jennifer ^b   Smith, Pete ^b   Smuts, Marlize ^a   Capparelli, Edmund ^c   Rosenkranz, Bernd ^d   Cotton, Mark ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ASPEN PHARMACARE; GENERIC DRUG; STAVUDINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; CAPSULES; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OFF-LABEL USE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY;

EID: 80055092971     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1876     Document Type: Article

References (10)

1. Zerit® (stavudine). Package insert and patient information leaflet 2010. Bristol-Myers Squibb, Princeton, NJ, USA.
2. Aspen Stavudine® (stavudine). Package insert and patient information leaflet 2006. Aspen Pharmacare, Port Elizabeth, South Africa.
3. Meyers T, Eley B, Loening W. Khomanani guidelines for the management of HIV-infected children. Johannesburg: National Department of Health: Jacana Media 2005.
4. US Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations. Revision 1. (Updated March 2003. Accessed 1 July 2009.) Available from http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM070124.pdf
5. Abdel-Rahman SM, Johnson FK, Gauthier-Dubois G, Weston IE, Kearns GL. The bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule. J Clin Pharmacol 2003; 43:148-153. (Pubitemid 36125941)
6. Lewis, LL, US Food and Drug Administration. Development of pediatric ARV drugs - FDA perspective. (Updated 1 June 2001 Accessed 14 June 2010.) Available from http://www. who.int/3by5/en/19lewis.ppt
7. Lyszkiewicz DA, Levichek Z, Kozer E, et al. Bioavailability of a pediatric amlodipine suspension. Pediatr Nephrol 2003; 18:675-678. (Pubitemid 36826853)
8. US Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: fixed dose combinations, co-packaged drug products, and single-entity versions of previously approved antiretrovirals for the treatment of HIV. Procedural (Updated October 2006. Accessed 14 June 2010.) Available from http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ ucm079742.pdf
9. Innes S, Smuts M, Cotton M, Seifart H, Rosenkranz B. Comparative study of different brands of stavudine capsules for the off-label 'opened capsule' dosing method recommended for HIV-infected infants and children in resource-limited settings. SAJCH 2009; 3:44-47.
10. Stavir® (stavudine). Patient information leaflet 2003. Cipla Life Sciences, Mumbai, India.